Skip to main content

Tagged With "News and Research"

Blog Post

Dupixent® Shows Positive Results in Phase 3 of Trial for Ages 6 to 11 With Severe Atopic Dermatitis

AAFA Community Services ·
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a pivotal Phase 3 trial evaluating Dupixent® (dupilumab) to treat severe atopic dermatitis in children aged 6 to 11 years met its primary and secondary endpoints. Dupixent is the first and only biologic to show positive results in this pediatric atopic dermatitis population.
Blog Post

Early Exposure to Pet and Pest Allergens Could Reduce Asthma Risk

AAFA Community Services ·
More than 8 percent of children in the U.S. currently have asthma. Did you know early exposure to some allergens may reduce a child’s asthma risk?
Blog Post

Eczema Is Much More Than a Childhood Disease

AAFA Community Services ·
Did you know eczema affects adults too? In fact, atopic dermatitis, the most common form of eczema, affects more than 16 million American adults. Help us raise awareness about eczema during Eczema Awareness Month by sharing the message below on social media.
Blog Post

Elijah E. Cummings Family Asthma Act Would Expand Efforts to Improve Care for People With Asthma

AAFA Community Services ·
Representatives Eliot L. Engel (D-NY-16), Fred Upton (R-MI-06), Pete King (R-NY-02) and TJ Cox (D-CA-21), all members of the House Asthma and Allergy Caucus, have introduced legislation to honor Elijah E. Cummings’ long-time advocacy for those living with asthma. The Elijah E. Cummings Family Asthma Act would expand federal, state, and local efforts to improve care for individuals with asthma.
Blog Post

EPA Works to Reduce Air Pollution in 32 States by Improving Older School Buses

AAFA Community Services ·
Today, the U.S. Environmental Protection Agency (EPA) awarded more than $8.7 million to replace or retrofit 452 older diesel school buses. The funds are going to 141 school bus fleets in 32 states, each of which will receive rebates through EPA's Diesel Emissions Reduction Act (DERA) funding. The new and retrofitted buses will reduce pollutants that are linked to health problems such as asthma and lung damage.
Blog Post

Family Keeps Memory of 13-Year-Old Sports Star Alive Through Asthma Awareness Efforts

AAFA Community Services ·
Tiffany Phu loved sports and spent most of her time outdoors. So it was fitting that on a balmy May night, her older sister Michelle confidently threw out the first pitch at a Philadelphia Phillies game. Michelle advocates for asthma awareness in memory of her sister Tiffany. “Tiffany enjoyed playing all types of sports,” notes Michelle. Tiffany died from asthma two years earlier, in May 2014, after running track at her Texas school. The eighth grader was just 13. The sudden and tragic loss...
Blog Post

FDA Approves a New Treatment Option for Those With Severe Asthma

AAFA Community Services ·
AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab) for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.
Blog Post

FDA Approves Cinqair to Treat Severe Asthma

AAFA Community Services ·
FDA News Release FDA approves Cinqair to treat severe asthma For Immediate Release March 23, 2016 Inquiries Media Andrea Fischer 301-796-0393 Consumers 888-INFO-FDA Release The U.S. Food and Drug Administration today approved Cinqair (reslizumab) for use with other asthma medicines for the maintenance treatment of severe asthma in patients aged 18 years and older. Cinqair is approved for patients who have a history of severe asthma attacks (exacerbations) despite receiving their current...
Blog Post

FDA Approves Dupixent® for Treatment of Asthma

AAFA Community Services ·
The FDA has approved another biologic treatment, Dupixent, for the treatment of both moderate and severe asthma patients with eosinophilic phenotype and oral corticosteroid-dependent asthma, regardless of phenotype.
Blog Post

FDA Approves Dupixent® for Chronic Rhinosinusitis With Nasal Polyps

AAFA Community Services ·
The U.S. Food and Drug Administration today approved Dupixent (dupilumab) to treat adults with nasal polyps (growths on the inner lining of the sinuses) accompanied by chronic rhinosinusitis (prolonged inflammation of the sinuses and nasal cavity). This is the first treatment approved for inadequately controlled chronic rhinosinusis with nasal polyps.
Blog Post

FDA Approves Dupixent® for Moderate-to-Severe Atopic Dermatitis in Adolescents

AAFA Community Services ·
Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupixent can be used with or without topical corticosteroids.
Blog Post

FDA Approves FASENRA® Pre-Filled Auto-Injector Pen for Self-Administration

AAFA Community Services ·
AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved the self-administration of FASENRA® (benralizumab) in a pre-filled, single-use auto-injector (the FASENRA Pen™).
Blog Post

FDA Approves First Generic ADVAIR DISKUS® for Asthma Treatment

AAFA Community Services ·
The U.S. Food and Drug Administration today approved the first generic of Advair Diskus (fluticasone propionate and salmeterol inhalation powder) for the twice-daily treatment of asthma in patients aged four years and older and maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD).
Blog Post Featured

FDA Approves First Generic Competitor of EpiPen Epinephrine Auto-Injector

AAFA Community Services ·
The U.S. Food and Drug Administration today approved the first generic version of EpiPen and EpiPen Jr (epinephrine) auto-injector for the emergency treatment of allergic reactions, including those that are life-threatening (anaphylaxis), in adults and pediatric patients who weigh more than 33 pounds. Teva Pharmaceuticals USA gained approval to market its generic epinephrine auto-injector in 0.3 mg and 0.15 mg strengths.
Blog Post

FDA Approves First Seasonal Influenza Vaccine Containing an Adjuvant

AAFA Community Services ·
The U.S. Food and Drug Administration approved Fluad, the first seasonal influenza vaccine containing an adjuvant.
Blog Post

FDA Approves New Flu Treatment

AAFA Community Services ·
Today, the U.S. Food and Drug Administration approved Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza (flu) in patients 12 years of age and older who have been symptomatic for no more than 48 hours.
Blog Post

FDA Approves Removal of Asthma-Related Death Box Warnings From Certain Asthma Medicines

AAFA Community Services ·
FDA's most prominent warning, the Boxed Warning, about asthma-related death has been removed from the drug labels of medicines that contain both an ICS and LABA. A FDA review of four large clinical safety trials shows that treating asthma with long-acting beta agonists (LABAs) in combination with inhaled corticosteroids (ICS) does not result in significantly more serious asthma-related side effects than treatment with ICS alone.
Blog Post

FDA Approves Symbicort to Treat Asthma In Children Ages 6-12

AAFA Community Services ·
AstraZeneca announced that the US Food and Drug Administration (FDA) approved SYMBICORT® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol 80/4.5 micrograms for the treatment of asthma in pediatric patients aged six up to 12 years.
Blog Post

FDA Approves Two New Asthma Inhalers

AAFA Community Services ·
[Press Release] Teva Announces FDA Approval of Two New RespiClick® Maintenance Inhalers for the Treatment of Asthma Approvals Expand Portfolio of Respiratory Medicines Delivered in RespiClick® Inhaler Designed to Eliminate the Need for Hand-Breath Coordination During Inhalation JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) announced that the U.S. Food and Drug Administration (FDA) approved two products for adolescent and adult patients with asthma.
Blog Post

FDA Considers Biologic Dupilumab for Children Ages 6 to 11 Years With Moderate-to-Severe Atopic Dermatitis

AAFA Community Services ·
Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) as an add-on maintenance treatment for children aged 6 to 11 years with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
Blog Post

FDA Extends Expiration Dates of Certain Lots of EpiPens®

AAFA Community Services ·
The U.S. Food and Drug Administration today took additional action to mitigate shortages of EpiPen (epinephrine) auto-injector by extending the expiration date of specific lots of 0.3 milligram products marketed by Mylan by four months beyond the labeled expiration date.
Blog Post

FDA Grants Breakthrough Therapy Designation for Tezepelumab for Severe Asthma

AAFA Community Services ·
AstraZeneca and its partner Amgen Inc. (Amgen) announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab in patients with severe asthma, without an eosinophilic phenotype, who are receiving inhaled corticosteroids/long-acting beta2-agonists with or without oral corticosteroids and additional asthma controllers.
Blog Post

FDA Will Consider Xolair for the Treatment of Nasal Polyps

AAFA Community Services ·
Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) for Xolair® (omalizumab) for the treatment of nasal polyps in adult patients 18 years of age and older with inadequate response to intranasal corticosteroids.
Blog Post

February Advocacy Update: Over-the-Counter Medicines, Restaurant Safety and Cleaner Cars

Jenna R. ·
Welcome to your February advocacy update. I’m Jenna Riemenschneider, director of advocacy at the Asthma and Allergy Foundation of America (AAFA). I am pictured above with AAFA board member Renuka Babu Brown and Senator Ed Markey's (D-MA) policy advisor Adam Axler. Over-the-Counter Drug Access and Cleaner Cars Rollbacks AAFA and other members of the Healthy Choices Coalition met with Representative Judy Chu's office. We asked her to co-sponsor the Restoring Access to Medication Act of 2019...
Blog Post

FeNO Testing Can Be a Helpful Part of Asthma Management

AAFA Community Services ·
Asthma is a chronic disease that causes your airways to be inflamed. The most common symptoms of asthma are coughing, shortness of breath, wheezing and chest tightness. But there are other diseases that can have the same symptoms of asthma. For your doctor to make the right diagnosis, it is important to know if your airways are inflamed.
Blog Post

Fighting for Air in Detroit, Michigan, the #16 Asthma Capital

AAFA Community Services ·
Shari Duncan has had asthma for more than three decades. In recent years it has become quite severe. Shari takes daily asthma maintenance medicines, does nebulizer breathing treatments and works hard to avoid her biggest asthma triggers. She also uses her quick-relief inhaler about once or twice a week. In spite of these efforts, four to six times a year Shari is hospitalized for asthma.
Blog Post

Find Out If Your Home Is Asthma and Allergy Friendly With Our Healthy Home Assessment

AAFA Community Services ·
June is National Healthy Homes Month. Your home can have a big impact on how well you manage your asthma and allergies. Reducing asthma triggers and allergens in your home should be an important part of your asthma and allergy management plan.
Blog Post Featured

Food Allergies and the Emotional, Social and Financial Impact

AAFA Community Services ·
AAFA released the My Life With Food Allergy: Parent Survey Report. This report summarizes the emotional, social and financial impact on the parent or caregiver of a child with food allergies.
Blog Post

Food Allergy Research Survey – Recruiting Now!

AAFA Community Services ·
This year’s theme for World Allergy Week is The Global Problem of Food Allergy. To help us take action on food allergies, we are seeking 1,000 individuals to fill out a survey that may take 15-30 minutes (the length of the survey depends on your answers).
Blog Post

Football Star Partners with Asthma Foundation to Help Kids Tackle Asthma

AAFA Community Services ·
The Asthma and Allergy Foundation of America (AAFA) and Rashad Jennings of the New York Giants today announced the launch of their #TackleAsthma campaign to educate and inspire children with asthma. As part of National Asthma and Allergy Awareness Month this May, AAFA and Jennings are working to help families understand and manage the daily challenges of living with asthma.
Blog Post

Free Training for Patients with Asthma to Learn About Research (Chattanooga)

AAFA Community Services ·
The Asthma and Allergy Foundation is holding a training session for patients, parents and/or caregivers of people with asthma to learn about research.
Blog Post

Funding Cuts to Medical Research Hurt People with Asthma and Allergies

Melanie Carver ·
All Americans, including people with asthma and allergies, have benefited from the important research provided by the National Institutes of Health (NIH).
Blog Post

UPDATED: GlaxoSmithKline Recalling Ventolin Inhalers for Possible Package Leakage

AAFA Community Services ·
Note: As of May 16, 2017, GlaxoSmithKline expanded their recall. Additional lot numbers have been added below. GlaxoSmithKline (GSK) issued a voluntary Class II recall on April 4, 2017 for three lots of Ventolin® HFA 200D Inhalers from U.S. hospitals, pharmacies, retailers and wholesalers as a precautionary measure. It is not a consumer recall.
Blog Post

GlaxoSmithKline Recalls Two Lots of Ventolin HFA Albuterol Sulfate Inhalers

AAFA Community Services ·
Some canisters may not contain sufficient propellant to deliver the labeled claim of 200 actuations through the end of shelf life.
Blog Post

GlaxoSmithKline Study Shows Nucala Improves Quality of Life, Lung Function in Severe Asthma

AAFA Community Services ·
GlaxoSmithKline plc (LSE/NYSE:GSK) today announced data demonstrating that severe asthma patients, whose disease is driven by eosinophilic inflammation, treated with first-in-class biologic Nucala® (mepolizumab) added-on to standard of care, achieved clinically and statistically significant improvements in their health-related quality of life and lung function, when compared to patients treated with placebo and standard of care. These results are from the phase IIIb MUSCA study (NCT02281318, 200
Blog Post

Global Climate Change Is a Rapidly Growing Health Emergency

AAFA Community Services ·
New research shows that climate change is already a significant public health issue and a looming global health emergency. Its findings, outlined in The Lancet medical journal, demonstrate the various ways climate change is already affecting the health of people across the planet, today.
Blog Post

Global Initiative for Asthma (GINA) Recommends the Use of Fractional Exhaled Nitric Oxide (FeNO) Monitoring for Difficult-to-Treat and Severe Asthma Management

AAFA Community Services ·
Circassia Pharmaceuticals, Inc. (“Circassia” or “the Company”), a specialty pharmaceutical company focused on respiratory disease, today announced that Fractional Exhaled Nitric Oxide (FeNO) monitoring is recommended in the latest Global Initiative for Asthma (GINA) guide, “Difficult-to-Treat & Severe Asthma in Adolescent and Adult Patients – Diagnosis and Management.”
Blog Post

GSK, Maker of ADVAIR DISKUS®, Announces Authorized Generic

AAFA Community Services ·
The Asthma and Allergy Foundation of America is sharing this press release from GlaxoSmithKline (GSK) to bring you the latest research news quickly. [PRESS RELEASE] GSK Announces Availability of Authorized Generic ADVAIR DISKUS® (fluticasone propionate/salmeterol inhalation powder) GSK announced today plans to make available an authorized generic (AG) of ADVAIR DISKUS (fluticasone propionate/salmeterol inhalation powder) in all three approved strengths. The authorized generic will be...
Blog Post

GSK to Offer Generic Version of Ventolin HFA Albuterol Inhaler

AAFA Community Services ·
The Asthma and Allergy Foundation of America is sharing this press release from GlaxoSmithKline to bring you the latest research news quickly. [PRESS RELEASE] GSK announces availability of Authorized Generic Albuterol Sulfate Inhaler for treatment or prevention of bronchospasm Effective, January 15, 2019, GSK announced the availability of an authorized generic (AG) of Ventolin HFA (albuterol sulfate) inhalation aerosol. The AG will be manufactured by GSK and distributed by Prasco LLC. The...
Blog Post

We Are Grateful for You!

AAFA Community Services ·
We are thankful for you! Thanks to people like you, adults with asthma and allergies, and families raising children with asthma and allergies, have hope for this holiday season.
Blog Post

Hardwood vs. Carpet: What Side Are You On?

AAFA Community Services ·
Before you update your flooring, you should know the pros and cons of the two most common options – hardwood and carpet. Style preference is one thing, but which is best for the health of your family? Which one do you think is more asthma and allergy friendly? It's important to learn the advantages and disadvantages of both when shopping for new flooring when you have asthma and allergies. It is important to stay up-to-date on ways to make your home asthma and allergy friendly . By joining...
Blog Post

Have AAFA's Resources Helped You Manage Asthma and Allergies?

AAFA Community Services ·
Will you take a moment and tell the world how AAFA has helped you manage asthma and allergies by sharing your story with GreatNonprofits? GreatNonprofits rates nonprofit organizations like ours. Your review allows us to gain visibility and support, so we can assist other families with asthma and allergies.
Blog Post

Health Insurance 101 for People With Asthma and Allergies (Video and Resources)

AAFA Community Services ·
The Asthma and Allergy Foundation of America (AAFA) hosted a webinar on Thursday, March 30, 2017, about Health Insurance 101 for People with Asthma and Allergies. Watch video on YouTube Our guest speaker was Prue Fitzpatrick, MPH, a member of the Board of Directors for AAFA. She has a background in health care policy, having been involved with recent health reform policy development and implementation, as well as experience working within the insurance industry. Ms. Fitzpatrick discussed:...
Blog Post

Healthier Home Initiative Addresses Philadelphia’s Asthma Crisis

AAFA Community Services ·
The asthma & allergy friendly® Certification Program partnered with the Children’s Hospital of Philadelphia to help 30 families in the region improve their indoor home environment.
Blog Post Featured

Help Others See Beyond Asthma and Allergies During National Asthma and Allergy Awareness Month

AAFA Community Services ·
Each May since 1984, the Asthma and Allergy Foundation of America (AAFA) has declared May to be National Asthma and Allergy Awareness Month. This month is dedicated to teaching others about asthma and allergies to create more awareness and understanding. We also want to help people see beyond asthma and allergies. This year, we aim to do just that through our themes, “More Than Asthma” and “More Than Food Allergies.”
Blog Post

Help People With Asthma and Allergies Through Federal Workplace Giving

AAFA Community Services ·
If you are a federal employee, consider making a difference in the lives of people with asthma and allergies with an easy donation through your paycheck. You likely know someone with asthma and allergies – or perhaps you are affected. According to the CDC, 1 in 14 people have asthma. In children, asthma is the leading cause for missed school days. Allergic disease is rising, affecting as many as 30% of adults and 40% of children. The Asthma and Allergy Foundation of America (AAFA) was...
Blog Post

Helping Doctors Provide Personalized Asthma Care – the CHAMPS Project

AAFA Community Services ·
Many consider personalized medicine the future of health care, and for good reason. As we learn about patients, genetics and diseases, we see that a standard approach is not the best. The purpose of personalized medicine is to provide custom treatment plans for patients. While customized care can help patients, it also adds challenges due to many factors that influence asthma.
Blog Post

High Heat, Air Pollution, Air Quality Create Problems for People with Asthma

AAFA Community Services ·
When we think of summer, we usually think of outdoor fun like swimming, cookouts, sporting events and going to the park. But with summer also comes a combination of heat and smog that can create bad air quality. Heat, air pollution and ragweed pollen create problems in the fall too. Since we spend more time outside in these warmer months, these combinations can be hard on your airways.
Blog Post

High School Athlete Doesn’t Let Asthma Stop Her

AAFA Community Services ·
Reilly Price takes both high school and community college classes. She is working on a senior research project. She serves as captain of her cross-country team, and dances for a pre-professional ballet company. She participates in student government and other campus clubs. On top of all this, Reilly also found time to raise money to help support Allergy and Asthma Foundation of America (AAFA).
Blog Post

Honor Student Holds Concert to Raise Awareness for Asthma and Allergies

AAFA Community Services ·
As a lifetime patient of both asthma and allergies, I am all too familiar with the late night ambulance trips to the emergency room because of an asthma attack or the rude interruption of a peanut or tree nut in my body at a classy restaurant. Such unfortunate circumstances are a constant fear in my life—just like they are for many others with asthma and severe allergies. Though my asthma has improved since I was a young child (I am now a passionate long distance runner—still running with my...
×
×
×
×